• Subscribe
  • Webinars
  • White Papers
  • Buyer's Guide
  • PhotonicsNXT
  • Get Published!
    • Recent Quotes
    My Watchlist
    Indicators
    LFW Photonics Market Index
    Markets
    Stocks
    ETFs
    Tools
    Overview
    News
    Currencies
    International
    Treasuries

    Betterlife Pharma Inc (OP: BETRF )

    0.0952 +0.0082 (+9.43%)
    Streaming Delayed Price Updated: 2:09 PM EDT, May 3, 2024 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    Price and Volume

    Detailed Quote
    Volume 11,600
    Open 0.0920
    Bid (Size) N/A (0)
    Ask (Size) N/A (0)
    Prev. Close 0.0870
    Today's Range 0.0898 - 0.0952
    52wk Range 0.0309 - 0.0952
    Shares Outstanding N/A
    Dividend Yield N/A
    Chart for (: )
    Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

    Top News

    More News
    BetterLife Announces Intent to Complete Private Placement of Units
    From BetterLife Pharma Inc.
    Via GlobeNewswire
    BetterLife Advances BETR-001 IND-enabling Studies
    From BetterLife Pharma Inc.
    Via GlobeNewswire

    Performance

    YTD
    +63.86%
    +63.86%
    1 Month
    +29.52%
    +29.52%
    3 Month
    +39.39%
    +39.39%
    6 Month
    +111.56%
    +111.56%
    1 Year
    +55.81%
    +55.81%

    More News

    Read More
    Psychedelics Headlines: Dementia Prevention, Psychological Flexibility, Ancient Romans' Trips And More
    Via Benzinga
    BetterLife To Present at the 2024 Bloom Burton & Co. Healthcare Investor Conference
    From BetterLife Pharma Inc.
    Via GlobeNewswire
    Psychedelics Headlines: Substitution Survey, Frank Herbert's Magic Mushrooms, Celestial Plans And News Review
    Via Benzinga
    BetterLife Announces Closing of $1.168 Million Convertible Debentures to Further Advance IND-enabling Studies of its Non-hallucinogenic LSD-based Drug Candidate BETR-001
    From BetterLife Pharma Inc.
    Via GlobeNewswire
    BetterLife Announces Closing of Convertible Debentures For Further Development of BETR-001
    From BetterLife Pharma Inc.
    Via GlobeNewswire
    BetterLife’s 2-Bromo-LSD for Treatment of Depression Highlighted by Carleton University
    From BetterLife Pharma Inc.
    Via GlobeNewswire
    BetterLife Announces Closing of a Private Placement
    From BetterLife Pharma Inc.
    Via GlobeNewswire
    BetterLife Announces Extension of Warrants
    From BetterLife Pharma Inc.
    Via GlobeNewswire
    BetterLife Pharma to Host Investors Update Call on September 18, 2023
    From BetterLife Pharma Inc.
    Via GlobeNewswire
    US Patent and Trademark Office Publishes BetterLife’s Comprehensive Patent for BETR-001 and Other LSD Derivatives
    From BetterLife Pharma Inc.
    Via GlobeNewswire
    BetterLife Obtains Favourable Animal Safety Data for Repeated Oral Dosing of BETR-001
    From BetterLife Pharma Inc.
    Via GlobeNewswire
    BetterLife Highlights BETR-001 Article in Technology Networks Drug Discovery and Announces Closing of a Private Placement
    From BetterLife Pharma Inc.
    Via GlobeNewswire
    Psyched: A $100M Donation Pledge, Frank Biden Gets Candid, New Search Trends & More
    Via Benzinga
    BetterLife Highlights American College of Physicians’ Updated Guidelines for Treating Depression and Announces Closing of Private Placement
    From BetterLife Pharma Inc.
    Via GlobeNewswire
    BetterLife Fast Tracks Its US Patent For Non-Hallucinogenic Compound And Other LSD Derivatives
    Via Benzinga
    BetterLife Fast Tracks Its US Patent for BETR-001 and Other LSD Derivatives
    From BetterLife Pharma Inc.
    Via GlobeNewswire
    BetterLife To Present BETR-001 Preclinical Data at the 32nd Annual Meeting of the International Behavioural Neuroscience Society (IBNS) in Niagara Falls, Ontario, Canada
    From BetterLife Pharma Inc.
    Via GlobeNewswire
    Psyched: Dubai Psychedelics Event, Key Receptor Discovered, Drew Barrymore, Oprah's Guest, Swiss MDMA & More
    Via Benzinga
    BetterLife's Non-Hallucinogenic LSD's Clinical Studies, Braxia's Psychedelic Treatments Continue
    Via Benzinga
    BetterLife Continues Progress on BETR-001 IND-Enabling Studies
    From BetterLife Pharma Inc.
    Via GlobeNewswire
    BetterLife To Present at the 2023 Bloom Burton & Co. Healthcare Investor Conference
    From BetterLife Pharma Inc.
    Via GlobeNewswire
    BetterLife To Present BETR-001 Preclinical Data at the 2023 Annual Meeting of the Society of Biological Psychiatry (SOBP) in San Diego, California
    From BetterLife Pharma Inc.
    Via GlobeNewswire
    BetterLife's Non-hallucinogenic LSD (BETR-001) For Treating Mood Disorders Highlighted in Drug Discovery & Development Article
    From BetterLife Pharma Inc.
    Via GlobeNewswire
    Data & News supplied by www.cloudquote.io
    Stock quotes supplied by Barchart
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the following
    Privacy Policy and Terms and Conditions.